Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 27, 2026EP EuropaceOpen Access

Predictors for non-persistence to edoxaban in Asian patients with atrial fibrillation: 2-year follow-up data from the ETNA-AF programme

View Full Paper
Ask AI
Bookmark
Share

Why the study?

What baseline characteristics predict non-persistence to edoxaban in Asian patients with nonvalvular atrial fibrillation?

Population

3,299 Asian patients with nonvalvular atrial fibrillation from South Korea, Taiwan, Thailand, and Hong Kong…

Design

Cohort

Follow-up

2 years

Authors

CWC C WangJCJ I ChoiNCN Y Chan

Discussion

Loading...

Member takes

Overview

Baseline predictors of edoxaban non-persistence signal need for adherence monitoring in NVAF; leaves optimal strategies open for prospective trials.

Key Points

  • The aim is to identify characteristics influencing non-persistence to edoxaban in Asian patients with atrial fibrillation during a 2-year follow-up.
  • Prospective, observational study of 3299 patients with nonvalvular atrial fibrillation (NVAF) from South Korea, Taiwan, Thailand, and Hong Kong.
  • Evaluated predictors of non-persistence and premature study termination using univariate Cox regression.
  • Adjusted for baseline characteristics, including CHA2DS2-VASc score.
  • 17% (n=561/3299) of patients were non-persistent with edoxaban after 2 years.
  • Higher body mass index (≥30 kg/m2) was associated with increased non-persistence (aHR 1.32 [1.00–1.74]).
  • Creatinine clearance <30 mL/min showed an even stronger association with non-persistence (aHR 2.04 [1.43–2.91]).

Structured PICO

What baseline characteristics predict non-persistence to edoxaban in Asian patients with nonvalvular atrial fibrillation?

P
Population
3,299 Asian patients with nonvalvular atrial fibrillation (NVAF) from South Korea, Taiwan, Thailand, and Hong Kong, median age 72.0 years, 41.1% female, median CHA2DS2-VASc score 3.0.
I
Intervention
Edoxaban
O
Outcome
Non-persistence (defined as permanent discontinuation of edoxaban) or premature study termination at 2 years follow-up

In Asian patients with nonvalvular atrial fibrillation, several clinical factors including severe renal impairment, chronic hepatic disease, and perceived frailty predict non-persistence to edoxaban at 2 years.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a3f97ce125782b61d865a14https://doi.org/10.1093/europace/euag105.1276
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of renal impairment and other high bleeding risk factors on clinical outcomes among Asian patients with atrial fibrillation on edoxaban: a post hoc analysis of the ETNA-AF program2026
  2. 2Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)2014 · 241 citations
  3. 3Impact of Age on Bleeding, Stroke, and Mortality in Edoxaban-Treated Patients with Atrial Fibrillation: Results from the ETAF-TR Registry2026
  4. 4CHA2DS2-VASc score-based anticoagulation management after catheter ablation for atrial fibrillation: a post-hoc analysis of the ALONE-AF trial2026
  5. 5Association of diabetes mellitus status and clinical outcomes of edoxaban in patients with atrial fibrillation: a sub-analysis from the ETNA-AF Asian registry2026